D&A at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s D&A?
- Kyverna Therapeutics, Inc. (KYTX) reported D&A of $351K in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s D&A changed year-over-year?
- Kyverna Therapeutics, Inc.'s D&A decreased by 29.9% year-over-year, from $501K to $351K.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s D&A?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s D&A has grown at a 2.7% compound annual growth rate (CAGR), from $1.71M to $1.8M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.